Skip to main content
. 2012 Jul 10;74(2):327–335. doi: 10.1111/j.1365-2125.2012.04182.x

Figure 1.

Figure 1

Mean rosiglitazone plasma concentration–time profiles following a single 4 mg dose of rosiglitazone co-administered with 120 mg febuxostat or matching placebo; linear (a) and logarithmic plots (b). Error bars represent SD; upper bars, febuxostat phase, and lower bars, placebo phase. Rosiglitazone + Febuxostat (Inline graphic); Rosiglitazone + Placebo (Inline graphic)